On September 10, 2020 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James F. Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020 (Press release, Checkpoint Therapeutics, SEP 10, 2020, View Source [SID1234564960]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 22nd Annual Global Investment Conference: Presentation on Monday, September 14, 2020, at 3:30 p.m. EDT
Cantor Virtual Global Healthcare Conference: Presentation on Wednesday, September 16, 2020, at 10:00 a.m. EDT
Lake Street Capital Markets 4th Annual Best Ideas Growth (BIG4) Conference: Virtual one-on-one meetings on Thursday, September 17, 2020
Webcasts of the presentations will be available on the Events page, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days following each presentation.

On September 10, 2020 Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that management will participate in the following conferences in the month of September and invites investors to join by webcast (Press release, Oncternal Therapeutics, SEP 10, 2020, View Source [SID1234564959]). Please see additional details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference (Virtual)

Title:
Oncternal Therapeutics (ONCT) Company Presentation

Date:

Wednesday, September 16th, 2020

Time:

10:30 am Eastern Time

Presenter:

James Breitmeyer, President & CEO

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)

Title:

Oncternal Therapeutics (ONCT) Company Presentation

Date:

Tuesday, September 22nd, 2020

Time:

4:10 pm Eastern Time

Presenter:

James Breitmeyer, President & CEO

Webcast Links:

Live webcasts of the presentations will be available online via a link from the investor relations page of the Company’s website at View Source, and the webcasts will be archived there for at least 30 days following the events.

On September 10, 2020 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, reported that it will present at the following virtual conferences in September (Press release, UroGen Pharma, SEP 10, 2020, View Source [SID1234564958]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference
Wednesday, September 16th
10:00AM Eastern Time
Cantor Virtual Global Healthcare Conference
Thursday, September 17th
4:00PM Eastern Time
A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

On September 10, 2020 Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, reported that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, on Monday, September 14, 2020, at 12:30 p.m. EDT (Press release, Galectin Therapeutics, SEP 10, 2020, View Source [SID1234564957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed on the conference’s website at View Source or on the Company’s website www.galectintherapeutics.com. Management will also be available for one-on-one meetings with investors throughout the conference, which runs September 14 – 16, 2020.

For additional information or to schedule a one-on-one meeting with Galectin, please contact your H.C. Wainwright representative or email [email protected].

On September 10, 2020 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate in a virtual fireside chat at the Morgan Stanley 18th Annual Conference on Sept. 15, 2020, at 9:30 a.m. EDT (Press release, Merck & Co, SEP 10, 2020, View Source [SID1234564956]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source